Member Info for Wildforce

Personally, I think even if anyone can make a spike protein vaccine ‘stronger’ , it doesn’t get round the issue of variation ?

Just a thought as ever?

Take care all ..

So t-cell targeting is on the agenda for biontech .. of course as we know it’s not a simple task .. any old t-cell won’t do .. they have to be highly specific and of high avidity to be effective .. we know a company already doing that don’t we !?

Take care .

Thanks .. just doesn’t seem right replying to myself lol !

Take care..

That should have read ‘some comments relevant to scancell’

AI does seem to be all the rage .. here is an interesting read .. some relevant to scancell I think ..

https://medcitynews.com/2023/01/from-jpm-week-trends-that-life-science-experts-are-watching-in-2023/

Thanks for your link cleaner.. will have a look ..

Take care …

Tend to agree .. nothing replaces human ingenuity and trial and error!

Take care..

Bringing it back to scancell .. although there is plenty of activity coming out of the JP Morgan healthcare conference currently on .. I just think right now is not the best time for scancell to get the best value for its assets .. there is a lot of data due fairly shortly .. and it’s looking promising from what we know .. and we won’t need a computer or machine to tell us if tumours are shrinking !

Now I’ve said that .. there will be a deal announced tomorrow lol !!

Take care all !

Here’s a more in depth write up of what they are doing together ..

https://pharmaphorum.com/news/biontech-buys-uk-based-ai-startup-instadeep-in-562m-deal/

Fascinating work ..

Take care all ..

Not the total 100m just part of it.. was reading the Financial Times article ..

The search for knowledge eh .. but Biontech had already invested at least £100M into the company previously anyway!?

Take care all ..

Interesting acquisition ?

https://www.businesslive.co.za/amp/bd/companies/healthcare/2023-01-10-biontech-to-acquire-british-ai-start-up-instadeep-for-about-562m/

Take care all ..

Interesting discussion about combination therapies and what it means for the patents of other parties .. ie extending the protection ?

This of course is one route to value for scancells technology but I think there is another .. they are going directly head to head with them too ..

“ The aim of this study is to investigate preliminary efficacy of Modi-1 vaccine(s), in an open labelled clinical trial, in participants with TNBC, SCCHN, RCC and HGSOC, powered to demonstrate that Modi-1 vaccines have potent anti-tumour activity.
In this trial, Modi-1/Modi-1v will be administered, either as monotherapy or in combination with a CPI (as standard of care).
In addition, an exploratory, randomised cohort will be included to assess the impact of Modi-1 (with or without pembrolizumab) in participants with SCCHN scheduled for resection surgery with curative intent.”

.. there are significant ‘mono therapy’ arms to this multi targeted trial !

It’s all very interesting !

Just some thoughts as ever ..

Take care all ..

Surely if mRNA vaccines can be quickly built targeting the entire spike protein then why not the modi1 peptides?

I must be missing something?

Take care all ..

Thanks for your thoughts ..

So simply targeting the modi1 citrulinated proteins is impossible with regards to current mRNA techniques?

Take care ..

You are spot on .. Biontech only have first dibs at an exclusive deal on scancells targets.

The thing is , they haven’t developed their mRNA vaccine yet .. they will open a research and development centre in partnership with the U.K. government to work on it .. hoping to put one into trial in September.

It’s all about targets … What will biontech know in a few days? … they will know if using modi1’s citrulinated peptides in patients with immune system is successfully targeting tumour cells via t-cells.

Now (this is the bit I’m speculating on) .. knowing that modi1’s targets work in patients with immune systems, could Biontech create mRNA vaccines using these targets in patients with compromised immune systems using their own cells (personalised) ?

It makes complete sense to me that however biontech might want to use modi1’s targets , they would be wise to see if they are working for scancell ?

Take care TF .. this is all really interesting stuff eh !

If the results in modi1 trial are as good as they were in mice .. could biontech afford to walk away from such an exclusive offer !?

Take care ..

Do you think Biontech are waiting to see the early results of the modi1 trial before advancing/cementing their already exclusive agreement on targeting modi1’s epitopes and turning it into a licensing deal??

From the deal RNS ..

“ These epitopes form the basis of Scancell’s first Moditope® development candidate, Modi-1. Upon completion of these studies, BioNTech will have the exclusive option to enter into a licence agreement for the development of cell receptor based therapeutics that are specific to Modi-1 epitopes.”

Fascinating times ..!

Take care ..

I wouldn’t write off Covidity too soon .. and don’t forget it’s being developed with the help of funds from U.K. Research and innovation ..

https://gtr.ukri.org/organisation/B15ECD41-022F-4DFF-B178-CBBC4CF0FB86

It’s not just us who are interested in the early results?

Take care all ..

Please keep that knowledge to yourself then lol .. particularly if you plan to go to the next AGM lol ..

The last sentence in that piece says it all ..

Take care !

Morning ! How the heck did you find that ! Lol ..

Nice work .. news spreading ..

Take care and thanks ..